Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results
ASHBURN, Va., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the third quarter, ended September 30, 2022.
- ASHBURN, Va., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the third quarter, ended September 30, 2022.
- During the quarter, we also established a website to facilitate patient awareness and participation in the study.
- In July 2022, Quoin Pharmaceuticals announced the opening of the first clinical site for its clinical study to evaluate QRX003 for the treatment of the rare genetic disease, Netherton Syndrome.
- A majority of clinical sites are now fully open and the remaining sites are expected to open in the fourth quarter of 2022.